drugset / Trial / NCT02548195

Oxaliplatin+Gemcitabine vs Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma

NCT02548195 ↗

Phase 3 Unknown 286 enrolled Shanghai Zhongshan Hospital
RandomizedParallel-groupOpen-labelPrevention

Summary

To evaluate of adjuvant therapy using oxaliplatin and gemcitabine (GEMOX regimen) versus capecitabine alone chemotherapy in patients who underwent curative surgery for intrahepatic cholangiocarcinoma (ICC) -- a randomized control study.

Timeline

Start
2015-07
Primary completion
2018-06
Completion
2018-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Capecitabine Small molecule 1250 mg/m2 —
Subject Gemcitabine Small molecule 1000 mg/m2 —
Subject Oxaliplatin Small molecule 85 mg/m2 —

Indications